Data di Pubblicazione:
2016
Abstract:
Acromegaly is a rare disease associated with significant morbidity and increased mortality. Treatment of acromegaly aims at controlling growth hormone hypersecretion, improving patients' symptoms and comorbidities and normalizing mortality. The therapeutic options for acromegaly include surgery, medical therapies and radiotherapy. However, despite all these treatment options, approximately one-half of patients are not adequately controlled. Progress in molecular research has made possible to develop new therapeutic strategies to improve control of acromegaly. This article will review the new medical approaches to acromegaly which consist in evolution of traditional therapeutic protocols and development of new molecules with different profiles of activity.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acromegaly; Antisense molecules; Botulin neurotoxin; Oral octreotide; Pasireotide; Somatostatin analogs; Acromegaly; Adenoma; Antineoplastic Agents, Hormonal; Botulinum Toxins; Cabergoline; Chemotherapy, Adjuvant; Dopamine Agonists; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Recombinant Fusion Proteins; Somatostatin; Endocrinology, Diabetes and Metabolism; Endocrinology
Elenco autori:
Maffezzoni, F.; Frara, S.; Doga, M.; Mazziotti, G.; Giustina, A.
Link alla scheda completa:
Pubblicato in: